TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23095185
Drug: DHA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA group (200 mg/day DHA)
Study: 16436239
Drug: Méniètt device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Méniètt device (local overpressure treatment)
Study: 14761073
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (8‐12 mg once a day)
Study: 14761073
Drug: Dihydropyridine calcium-channel
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydropyridine calcium-channel blockers (DCCBs)
Study: 10872643
Drug: tolcapone 50
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tolcapone 50 mg
Study: 9591224
Drug: tolcapone 200
Normalized name: tolcapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone 200 mg
Study: 10872643
Drug: tolcapone 400
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tolcapone 400 mg
Study: 10872643
Drug: tolcapone (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone (various doses)
Study: 1984381
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (2 mg, 4 mg, placebo)
Study: 6138061
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of midazolam
Study: 6138061
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of midazolam
Study: 6138061
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of midazolam
Study: 29863387
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of tiagabine/day
Study: 29863387
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg of tiagabine/day (placebo)
Study: 22299805
Drug: Prize-based contingency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prize-based contingency management (CM) intervention contingent on submitting negative urine drug screens (UDS)
Study: 19185539
Drug: Pregabalin (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (exact dosage and duration not specified)
Study: 17397610
Drug: Sodium heparin
Normalized name: Heparin Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium heparin 100 IU (study 1)
Study: 17397610
Drug: Sodium heparin
Normalized name: Heparin Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium heparin 500 IU (control 1)
Study: 17397610
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (SS) (study 2)
Study: 17397610
Drug: Sodium heparin
Normalized name: Heparin Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium heparin 100 IU (control 2)
Study: 10519944
Drug: 20 microg
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg of MSP-1(19) vaccine
Study: 10519944
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg of MSP-1(19) vaccine
Study: 10519944
Drug: Control vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccines (hepatitis B or Td)
Study: 2209838
Drug: Early second
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early second surgery after three cycles of cis-platinum-based chemotherapy (median of 14 weeks from initial laparotomy)
Study: 7202896
Drug: metoprolol up
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol up to 200 mg bid
Study: 7202896
Drug: methyldopa up
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methyldopa up to 500 mg bid
Study: 31740343
Drug: Ibandronate (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (150 mg/month)
Study: 31740343
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D (daily)
Study: 31740343
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (226 healthy premenopausal women receiving no treatments)
Study: 27611235
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy-Enhanced (CBT-E)
Study: 27611235
Drug: Integrative Cognitive-Affective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Cognitive-Affective Therapy for BN (ICAT-BN)
Study: 23565841
Drug: High-flavanol chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavanol chocolate (40g dose)
Study: 23565841
Drug: Low-flavanol chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flavanol chocolate (40g dose)
Study: 23565841
Drug: High-flavanol chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavanol chocolate (20g daily intake for 12 weeks)
Study: 23565841
Drug: Low-flavanol chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flavanol chocolate (20g daily intake for 12 weeks)
Study: 19208728
Drug: Somatostatin analogs
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin analogs (SSA) treatment
Study: 15494100
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg E(2)V + 5 mg MPA
Study: 15494100
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg E(2)V + 2.5 mg MPA
Study: 11806199
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (intravenous and supravenous)
Study: 10193280
Drug: i.v. ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketamine 10 mg i.v. bolus followed by 10 mg h‐1 infusion for 48 h
Study: 8164327
Drug: PGE1 infusion
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 infusion at a rate of 30 ng.kg‐1 x min‐1 during surgery and 10‐30 ng.kg‐1 x min‐1 after surgery
Study: 8164327
Drug: No PGE1
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No PGE1 infusion (control group)
Study: 3284285
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy with mechanical ventilation (Group B)
Study: 3284285
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy only (Group A)
Study: 24282495
Drug: Joint Crisis
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint Crisis Plans (JCP) plus treatment as usual (TAU)
Study: 21955538
Drug: Stroke volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroke volume guided intra‐operative fluid management using LiDCOplus with maintenance fluid and 250 ml colloid boluses to achieve sustained 10% increases in stroke volume
Study: 21955538
Drug: Fluid administration
Normalized name: Fluid Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid administration at the responsible (blinded) anaesthetist's discretion
Study: 16534549
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg/day) continued for 6 weeks in group A
Study: 16534549
Drug: Atorvastatin withdrawn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin withdrawn in group B
Study: 16534549
Drug: Atorvastatin started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin started in groups C and D for 6 weeks
Study: 16534549
Drug: Atorvastatin withdrawn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin withdrawn in group C after 6 weeks
Study: 16534549
Drug: Atorvastatin continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin continued in group D after 6 weeks
Study: 14559927
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times daily for 21 days
Study: 10468218
Drug: L-DOPA treatment
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPA treatment in PD patients
Study: 25853905
Drug: 2-mg intraventricular
Normalized name: cerliponase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg intraventricular TPA every 12 hours
Study: 24012128
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic treatment (group 1)
Study: 24012128
Drug: Local antibiotic
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local antibiotic treatment (group 2)
Study: 21835135
Drug: Mepolizumab (0.55,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (0.55, 2.5, or 10 mg/kg) administered every 4 weeks for a total of 3 infusions
Study: 17942818
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg IV
Study: 17942818
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg IV (subgroup with migraine lasting longer than 72 hours)
Study: 9506650
Drug: Milrinone lactate
Normalized name: milrinone lactate
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone lactate (50 microg/kg loading dose, then 0.5 microg/kg/min infusion)
Study: 9506650
Drug: Milrinone lactate
Normalized name: milrinone lactate
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone lactate (after discontinuation of infusion)
Study: 9506650
Drug: Milrinone lactate
Normalized name: milrinone lactate
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone lactate (during infusion)
Study: 7635035
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human growth hormone (GH)
Study: 3051628
Drug: Orchiectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchiectomy plus combined hormone and chemotherapy (ethinylestradiol sulfonate plus vincristine/vinblastine, cyclophosphamide, methotrexate)
Study: 3051628
Drug: Orchiectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchiectomy plus antigonadotropic therapy alone (ethinylestradiol sulfonate)
Study: 3051628
Drug: Orchiectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchiectomy plus chemotherapy (vincristine/vinblastine, cyclophosphamide, methotrexate)
Study: 15159134
Drug: Valerian extract
Normalized name: valerian extract
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian extract (600, 1200, and 1800 mg)
Study: 9222733
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg once daily in the morning
Study: 9222733
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg once daily in the evening
Study: 28725977
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (60,000 IU orally, weekly for 4 weeks) and calcium supplements (500 to 1,000 mg/day for 3 months)
Study: 23279924
Drug: Past 30‐day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Past 30‐day daily average number of cigarettes smoked
Study: 21991566
Drug: Post-operative treatment
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative treatment with FPANS 100 μg q.i.d.
Study: 21991566
Drug: Not treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not treated post-operatively with topical glucocorticoids
Study: 17192770
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg rifampin (intravenous 30-min infusion)
Study: 2737307
Drug: High-dose single
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose single agent cisplatinum (19 patients)
Study: 30646391
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg THC (smoked)
Study: 30646391
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg THC (vaporized)
Study: 30646391
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg THC (smoked)
Study: 30646391
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg THC (vaporized)
Study: 27500873
Drug: Pregabalin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (up to 600 mg a day for six days)
Study: 24812898
Drug: Chinese medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medical enema for brain resuscitation, relieving rigidity of muscles and activating collaterals for 14 days, alongside comprehensive rehabilitation training and intravenous Monosialotetrahexosylganglioside Sodium Injection for 10 days
Study: 24812898
Drug: Comprehensive rehabilitation
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive rehabilitation training and intravenous Monosialotetrahexosylganglioside Sodium Injection for 10 days
Study: 23176129
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of calcium carbonate combined with 400 IU of vitamin D(3)
Study: 12544314
Drug: Terazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (1 to 5 mg daily for 14 weeks)
Study: 10817352
Drug: Neoadjuvant chemoendocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoendocrine therapy followed by surgery
Study: 10817352
Drug: Adjuvant chemoendocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemoendocrine treatment after primary surgery
Study: 9862047
Drug: Neoadjuvant chemoendocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoendocrine therapy
Study: 6825540
Drug: Granulated pancreatic
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulated pancreatic enzyme preparation (Pankreon)
Study: 7990068
Drug: Psychological preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological preparation
Study: 31340899
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (basic preparation)
Study: 30134990
Drug: Parenting intervention
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenting intervention providing training in dialogic book-sharing, conducted weekly for 7 weeks.
Study: 24445955
Drug: Extended caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended caffeine treatment
Study: 22585223
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg moxifloxacin and 900 mg rifapentine twice weekly
Study: 22585223
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg moxifloxacin and 1,200 mg rifapentine once weekly
Study: 17355800
Drug: Remifentanyl infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanyl infusion at 0.1 microg x kg(‐1) x min(‐1)
Study: 17355800
Drug: Fentanyl bolus
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl bolus injection at 1.5 microg x kg(‐1)
Study: 17355800
Drug: Remifentanyl infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanyl infusion
Study: 17355800
Drug: Fentanyl bolus
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl bolus injection
Study: 15833578
Drug: mecamylamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: mecamylamine (10 mg)
Study: 1683411
Drug: tertatolol 5
Normalized name: tertatolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tertatolol 5 mg o.d.
Study: 31420397
Drug: Usual prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual prophylaxis strategy up to month +6 followed by pre-emptive therapy up to month +12
Study: 30066184
Drug: Thermoplastic aligners
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermoplastic aligners (clear transparent PET-G thermoplastic sheets)
Study: 26963896
Drug: Rapid intravenous
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid intravenous rehydration (3 litres Hartman's solution over 6 hours) and ongoing midwifery telephone support
Study: 23298702
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (30-minute musical session with headset)
Study: 21466589
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment (0.1%)
Study: 17074021
Drug: rebamipide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rebamipide (100 mg, t.i.d.)
Study: 14561278
Drug: Oral creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral creatine supplementation (5 g d(‐1) for six weeks)
Study: 27472572
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Dexamethasone and Ondansetron
Study: 27472572
Drug: Dexamethasone, Ondansetron,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, Ondansetron, Combination
Study: 20932179
Drug: Daily salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily salt intake measurement
Study: 18325757
Drug: Testosterone-in-adhesive matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone-in-adhesive matrix patch (4.8 mg testosterone daily, 2 patches of 60 cm2 every 48 hours)
Study: 18325757
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone enanthate injection (every 3 weeks)
Study: 11216754
Drug: Lexipafant 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lexipafant 10 mg
Study: 11216754
Drug: Lexipafant 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lexipafant 100 mg
Study: 9010144
Drug: Six months
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six months of oral anticoagulant therapy
Study: 9010144
Drug: Indefinite oral
Normalized name: TITANIUM DIOXIDE 3.25 mL in 35 mL CUTANEOUS CREAM [PHYTOGENIC INFINITE FOUNDATION SPF20 NB21]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indefinite oral anticoagulant therapy
Study: 3321865
Drug: Vasopressin antagonist
Normalized name: Vasopressin antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin antagonist (1‐deamino‐2‐D‐Tyr(OEt)‐4‐Thr‐8‐Orn‐oxytocin) 10 micrograms/kg body weight
Study: 30397714
Drug: Knowledge assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge assessment of dental hygienists regarding systemic diseases and oral health
Study: 26955679
Drug: Jiakangling Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiakangling Capsule (JC) combined with reduction of 131I (50-80 microCi per gram of thyroid tissue) taken for one month after 131I treatment.
Study: 26955679
Drug: Jiakangling Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiakangling Capsule (JC) combined with reduction of 131I.
Study: 18201433
Drug: Control (Inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Inhaled Fluticasone Propionate)
Study: 22045080
Drug: Adenosine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (both doses)
Study: 9470002
Drug: L-Thyroxine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Thyroxine (8 micrograms/kg birthweight per day)
Study: 29445858
Drug: L-Thyroxine
Normalized name: L-Thyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Thyroxine
Study: 2505682
Drug: 5-FU +
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU + PSK (3 g/day for 4 weeks and 5-FU 150 mg/day for 4 weeks, 10 courses)
Study: 26357419
Drug: 1.5 L
Normalized name: NUTREN 1.5 LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 L daily of EVIAN water on top of usual intake for 50 days
Study: 25033919
Drug: Acupuncture (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (twice a week for 4 weeks)
Study: 21256670
Drug: Placebo (sham-acupuncture,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham-acupuncture, twice a week for 4 weeks)
Study: 17761230
Drug: DASH diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASH diet (rich in fruits, vegetables, and low-fat dairy products) at intermediate sodium level (2,300 mg/day)
Study: 17761230
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet at intermediate sodium level (2,300 mg/day)
Study: 15669554
Drug: Estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (2 mg) and trimegestone (TMG 0.25 or 0.5 mg)
Study: 8294170
Drug: Ketoprofen 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 2.5% gel applied twice a day for seven days (250 mg per day)
Study: 8294170
Drug: Ketoprofen 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 2.5% gel
Study: 3327724
Drug: Aminophylline (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (1.5 mg/kg)
Study: 29402711
Drug: Tamsulosin alone:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin alone: 0.2 mg/d
Study: 29402711
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg/d plus celecoxib: 200 mg/d
Study: 27281374
Drug: Drug Attention
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug Attention Control Training Program (Drug‐ACTP)
Study: 25428341
Drug: Fluoxetine hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine hydrochloride dispersible tablet (Control)
Study: 23713299
Drug: Chemotherapy (Navelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Navelbine and cisplatin)
Study: 16600816
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) supplementation at doses of 1.35, 2.7, or 4.05 g/d for 12 weeks
Study: 10867111
Drug: R121919 (5-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: R121919 (5-40 mg)
Study: 10867111
Drug: R121919 (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: R121919 (40-80 mg)